In brief
- A team at the MD Anderson Cancer Center (Houston) reports in Science that psilocybin, when administered before chemotherapy, prevents peripheral nerve damage in mice caused by drugs such as cisplatin, paclitaxel, or docetaxel.
- The protective effect persisted throughout several treatment cycles and did not reduce the efficacy of the drug against the tumor.
- The mechanism involves the 5-HT2A serotonin receptor and is independent of the psychedelic effect: a non-hallucinogenic compound that activates the same receptor achieved similar protection.
Researchers at the MD Anderson Cancer Center in Houston have described a use for psilocybin in Science that has nothing to do with mental health. In mice, two doses administered before chemotherapy were sufficient to protect nerve endings against the damage typically caused by cisplatin and taxanes, two of the most widely used families of cytostatic drugs in oncology.
A problem without good solutions
Chemotherapy-induced peripheral neuropathy manifests as tingling, numbness, or pain in the hands and feet. It can force a reduction in the dosage of cancer treatment and, in many cases, persists for years after treatment has ended. There is no drug that reliably prevents it, and this gap is what the team led by Moran Amit and Patrick Dougherty identifies as the motivation for their work. Amit summarizes it this way: we need something that prevents nerve injury without interfering with life-saving chemotherapy.
What the data shows
Mice that received psilocybin before cisplatin, paclitaxel, or docetaxel retained touch sensitivity and did not develop the cold hypersensitivity characteristic of this type of damage. The effect was sustained throughout repeated chemotherapy cycles. The key, according to the authors, lies in the 5-HT2A serotonin receptor: blocking it eliminated the protection, and a compound without hallucinogenic properties capable of activating that same receptor obtained an equivalent result, which separates the neuroprotective effect from the subjective experience of the psychedelic trip. The fine detail of the mechanism points to the mitochondria: cisplatin depletes them and slows their movement within nerve fibers, while psilocybin activated a signaling pathway that maintained that transport and, with it, the energy available at the nerve endings. The tumors in the treated animals did not grow more or less than those in the control group, a finding the researchers emphasize because it clears up the obvious doubt: protecting the nerve did not also protect the tumor.
What this implies
This is work in mice, and it should be treated as such: what works in an animal model does not always translate to the clinic. The team itself presents it as a starting point. A phase 2 trial, dubbed NeuroGuard (NCT07227909), is already planned to test psilocybin during chemotherapy in patients with various types of cancer to see if the mechanism holds up outside the laboratory. The interesting thing about the finding is that it expands the playing field for this substance far beyond depression or palliative care, toward a preventive and purely physical use. And it fits with something that should be repeated whenever we talk about harm reduction: understanding how a substance acts, without prejudice or moral shortcuts, is what allows us to take advantage of its useful effects wherever they appear.
Source
- MD Anderson Cancer Center. Psilocybin prevents chemotherapy-related nerve injury and associated symptoms in preclinical models. UT MD Anderson Newsroom, regarding the article published in Science, September 3, 2026.
Educational content written from a harm reduction perspective and with respect for individual freedom. It is not a substitute for advice from a healthcare professional and is not intended to encourage or condemn any drug use.
